A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Haematologica. 2020 Jan;105(1):e26-e28. doi: 10.3324/haematol.2019.220012. Epub 2019 May 9.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azepines
  • B-Lymphocytes
  • Depsipeptides*
  • Humans
  • Lymphoma, T-Cell*
  • Lymphoma, T-Cell, Peripheral* / drug therapy
  • Neoplasm Recurrence, Local
  • Pyrimidines
  • Treatment Outcome

Substances

  • Azepines
  • Depsipeptides
  • MLN 8237
  • Pyrimidines
  • romidepsin